SI1501495T1 - Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori - Google Patents

Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori

Info

Publication number
SI1501495T1
SI1501495T1 SI200331922T SI200331922T SI1501495T1 SI 1501495 T1 SI1501495 T1 SI 1501495T1 SI 200331922 T SI200331922 T SI 200331922T SI 200331922 T SI200331922 T SI 200331922T SI 1501495 T1 SI1501495 T1 SI 1501495T1
Authority
SI
Slovenia
Prior art keywords
treatment
helicobacter pylori
pleuromutilins
disorders caused
pleuromutilin
Prior art date
Application number
SI200331922T
Other languages
Slovenian (sl)
Inventor
Gerd Ascher
Johannes Hildebrandt
Original Assignee
Nabriva Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics Ag filed Critical Nabriva Therapeutics Ag
Publication of SI1501495T1 publication Critical patent/SI1501495T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of preventing or treating diseases mediated by Helicobacter pylori, comprising administering to a subject in need of such treatment an effective amount of pleuromutilin.
SI200331922T 2002-04-23 2003-04-22 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori SI1501495T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0209262.5A GB0209262D0 (en) 2002-04-23 2002-04-23 Organic compounds
PCT/EP2003/004173 WO2003090740A1 (en) 2002-04-23 2003-04-22 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
EP03732288A EP1501495B1 (en) 2002-04-23 2003-04-22 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori

Publications (1)

Publication Number Publication Date
SI1501495T1 true SI1501495T1 (en) 2011-01-31

Family

ID=9935350

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331922T SI1501495T1 (en) 2002-04-23 2003-04-22 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori

Country Status (12)

Country Link
US (1) US7790749B2 (en)
EP (1) EP1501495B1 (en)
JP (1) JP2005529131A (en)
AT (1) ATE480232T1 (en)
AU (1) AU2003239813A1 (en)
DE (1) DE60334094D1 (en)
ES (1) ES2354972T3 (en)
GB (1) GB0209262D0 (en)
HK (1) HK1073250A1 (en)
SI (1) SI1501495T1 (en)
TW (1) TW200306294A (en)
WO (1) WO2003090740A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2014645A1 (en) * 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives and their use as antimicrobials
EP2159220A1 (en) 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
CN102924350B (en) * 2012-10-31 2014-04-09 中国农业科学院兰州畜牧与兽药研究所 Pleuromutilin derivatives, and preparation method and application thereof
CN103265442B (en) * 2013-06-05 2017-02-08 北京理工大学 Novel pleuromutilin derivatives, as well as preparation method and anti-tumour application thereof
TWI762573B (en) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 Purification of pleuromutilin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3560511D1 (en) * 1984-02-17 1987-10-01 Sandoz Ag Pleuromutilin derivatives, process for their preparation and their use
CA2042138A1 (en) 1990-04-18 1992-11-09 Hiroo Abe Agents for preventing or treating bacterial diseases of fishes
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6972297B2 (en) * 2000-04-04 2005-12-06 Smithkline Beecham P.L.C. 2-Hydroxy-mutilin carbamate derivatives for antibacterial use
DE10030781A1 (en) 2000-06-29 2002-01-17 Hassan Jomaa Combination preparations of 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives with special active pharmaceutical ingredients
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
PE20020676A1 (en) * 2000-09-13 2002-08-27 Biochemie Gmbh MUTILIN COMPOUNDS AS ANTIBACTERIAL
GB0024811D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
ATE480232T1 (en) 2010-09-15
AU2003239813A1 (en) 2003-11-10
US20050131023A1 (en) 2005-06-16
EP1501495B1 (en) 2010-09-08
DE60334094D1 (en) 2010-10-21
JP2005529131A (en) 2005-09-29
TW200306294A (en) 2003-11-16
ES2354972T3 (en) 2011-03-21
US7790749B2 (en) 2010-09-07
GB0209262D0 (en) 2002-06-05
HK1073250A1 (en) 2005-09-30
EP1501495A1 (en) 2005-02-02
WO2003090740A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
HK1073250A1 (en) Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
PL374865A1 (en) Treatment of tnf alpha related disorders
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
ZA200407216B (en) Tuberculosis treatment.
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
UA85055C2 (en) Use of myostatin (gdf8) inhibitor in conjunction with corticosteroid for treating neuromuscular disorder
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
MXPA04009929A (en) Treatment of gastroparesis.
PL374177A1 (en) Methods of treating hepatitis
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
UA86570C2 (en) Method of treating necrotizing enterocolitis
PL1694354T3 (en) Method for preventing and treating diabetes using neurturin
MXPA04004306A (en) Use of endothelin receptor antagonists in the treatment of tumour diseases.
MXPA03011270A (en) Use of rank antagonists to treat cancer.
WO2003103699A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
AU4578501A (en) Method for treating congestive heart failure
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
BR0312393A (en) Exemestane Infertility Treatment
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer